PDCD1 and neoplasm: Furthermore, CSF1R-p53KO mice treated with APR-246 plus anti–PD-1 resulted in loss of tumor control and worse survival benefit compared with CSF1R-p53WT mice treated with the same regimen (Figure 3C).